Abstract #3835

Diffusion and contrast-enhancement MRI phenotypes predict immune cell infiltration in brain metastases

Francesco Sanvito^1,2, Sonoko Oshima^1,2, Eileen Shiuan³, Lu Sun⁴, Nicholas S Cho^1,2, Asher Kim⁵, Noriko Salamon², Benjamin M Ellingson^1,2, Robert Prins⁴, Won Kim⁴, and Jingwen Yao^1,2

¹Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, University of California Los Angeles, Los Angeles, CA, United States, ²Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States, ³Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, United States, ⁴Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States, ⁵Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, United States

Synopsis

Keywords: Tumors (Post-Treatment), Treatment

Motivation: Immune checkpoint inhibitors (ICIs) can promote immune cell infiltration and increase anti-tumoral immune response in brain metastases (BM). Imaging proxies of immune infiltration would facilitate ICI-response monitoring in BM.

Goal(s): To test whether the combined assessment of diffusion and contrast-enhancement MRI phenotypes can provide insights into microscopic immune infiltration.

Approach: We studied the associations of diffusion and contrast-enhancement MRI phenotypes with histological immune cell infiltration and with ICI-treatment status

Results: Correlation analysis showed that high diffusivity and pronounced contrast-enhancement were positively associated with increased immune cell infiltration and were more likely observed in ICI-treated lesions.

Impact: Immune checkpoint inhibitors (ICIs) can promote immune cell infiltration and increase anti-tumoral immune response in brain metastases (BM). Diffusion and contrast-enhancement MRI phenotypes provide potential imaging biomarkers to non-invasively monitor tissue changes related to anti-tumoral immune response following ICIs.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.